Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
December 8, 2025BloodOpen Access

Haplo-identical transplantation in patients with myelofibrosis, a phase 2 prospective multicentric study

View Full Paper
Ask AI
Bookmark
Share

Authors

MRMarie RobinMRMarie-Thérèse RubioFSFelipe Suarez

Discussion

Loading...

Member takes

Overview

Clinical trial showed haplo-identical transplantation improved relapse survival in myelofibrosis patients, suggesting better donor options.

Key Points

  • To evaluate the effectiveness of haplo-identical transplantation in myelofibrosis patients lacking HLA-matched donors.
  • Phase 2 clinical trial with haplo-identical donors
  • Inclusion of patients aged 18-70 with various myelofibrosis characteristics
  • Cumulative incidence measured for various outcomes, including survival and GVHD
  • One-year relapse and rejection-free survival was 64.3%, higher than the historical 35%
  • Cumulative incidence of grade 2-4 acute GVHD was 64.3%
  • Median age of participants was 65, with a substantial proportion having primary myelofibrosis

Cite This Study

Robin et al. (2025) studied this question.

synapsesocial.com/papers/69362f7d4fa91c937236e509https://doi.org/10.1182/blood-2025-506
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Allogeneic hematopoietic stem cell transplantation for myelofibrosis; Patterns, treatment and outcome after relapse and long-term follow up.2025
  2. 2Real-World Challenges of Haplo-Identical Hematopoietic Stem Cell Transplant in a Developing Country: A Single Center Experience2024 · 1 citations
  3. 3The Two-Step Allogeneic Stem Cell Transplant Is Associated with Excellent Engraftment, Improved Survival and Low Nonrelapse Mortality in Patients with Myelofibrosis2026
  4. 4An evolving landscape – how changing conditioning regimes can improve myelofibrosis transplant outcomes.2025
  5. 5Allogeneic hematopoietic stem cell transplantation for hematological malignancies using nonmyeloablative fludarabine, cyclophosphamide, 200 centigray total body irradiation, and post-transplant cyclophosphamide, sirolimus, and mycophenolate mofetil for graft-versus-host disease prophylaxis is associated with low non-relapse mortality.2025